Wedbush reiterates Outperform on Damora Therapeutics

0 min read     Updated on 12 Jun 2026, 07:51 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Wedbush analyst David Nierengarten reaffirmed an Outperform rating for Damora Therapeutics, maintaining a price target of $35. The rating covers the NASDAQ-listed stock under ticker DMRA.

powered bylight_fuzz_icon
42819659

*this image is generated using AI for illustrative purposes only.

Wedbush analyst David Nierengarten has reaffirmed an Outperform rating for Damora Therapeutics, maintaining a price target of $35. The rating applies to the company listed on NASDAQ under the ticker DMRA.

The reiteration underscores the analyst's continued confidence in the stock's performance potential. No specific changes to the financial outlook or operational metrics were detailed in the update.

What upcoming catalysts or milestones could drive Damora Therapeutics toward the $35 price target?

How might broader market conditions affect the stock's ability to reach the projected target?

Are there any anticipated changes in Damora's pipeline or partnerships that could influence future performance?

like18
dislike

HC Wainwright initiates coverage on Damora Therapeutics with Buy rating

0 min read     Updated on 11 Jun 2026, 05:36 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

HC Wainwright & Co. analyst Mitchell S. Kapoor initiated coverage on Damora Therapeutics with a Buy rating and a price target of $45. The company is listed on NASDAQ under the ticker DMRA.

powered bylight_fuzz_icon
42725186

*this image is generated using AI for illustrative purposes only.

HC Wainwright & Co. analyst Mitchell S. Kapoor has initiated coverage on Damora Therapeutics with a Buy rating and a price target of $45. The rating highlights the firm's positive outlook on the company's performance and future prospects.

Damora Therapeutics is listed on NASDAQ under the ticker symbol DMRA. The initiation of coverage provides a new benchmark for investors evaluating the stock's potential.

Key Details

Aspect Details
Rating Buy
Price Target $45
Exchange NASDAQ
Ticker Symbol DMRA
Analyst Mitchell S. Kapoor

What upcoming clinical milestones could drive Damora Therapeutics toward the $45 price target?

How might the broader biotech sector trends influence DMRA's performance in the coming months?

What competitive advantages does Damora Therapeutics have that justify the Buy rating?

like19
dislike